LFCR

#3707
Lifecore Biomedical, Inc. - Common Stock
4.5 5 USD
0.00%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
4.53
4.58
Year Range
3.63
8.98
Daily Change
+0.22%
Monthly Change
+4.12%
6 month change
-37.59%
Year Change
-40.21%
Previous Close
4.5 4
Open
4.5 3
Low
4.5 3
High
4.5 8
Volume
21
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q1 FY2026
8-K

2025

Current report, Q4 FY2025
LIFECORE BIOMEDICAL, INC. current report, Q4 FY2025
8-K

LIFECORE BIOMEDICAL, INC. current report, Q4 FY2024

Full document

Business Context and Reporting Period

Lifecore Biomedical, Inc. (LFCR) filed this Form 8-K to report the results of its 2024 Annual Meeting of Stockholders held on November 7, 2024. The record date for the meeting was October 4, 2024.

Key Financial Metrics

This filing is a Current Report regarding corporate governance and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Voting Results

The filing details the outcomes of three proposals submitted to stockholders:

  • Director Elections: Stockholders elected five directors. Four were elected by Common and Series A Preferred Stockholders voting as a single class, and one (Christopher Kiper) was elected solely by Series A Preferred Stockholders.
  • Accounting Firm Ratification: Stockholders ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending May 25, 2025.
  • Executive Compensation: Stockholders approved a non-binding advisory proposal regarding executive compensation.

Voting Statistics:

  • Director Nelson Obus: Received 21,721,070 votes for and 2,115,224 votes against.
  • Director Katrina Houde: Received 20,973,514 votes for and 2,827,981 votes against.
  • Accounting Firm Ratification: Received 31,279,291 votes for and 29,609 votes against.
  • Compensation Advisory Vote: Received 23,645,284 votes for and 163,003 votes against.

Guidance, Outlook, and Risks

The filing text does not provide guidance, outlook, management commentary on future operations, risks, contingencies, or unusual items.

Investor Verification Checklist

  • Verify the composition of the new Board of Directors and the specific terms of office.
  • Review the full proxy statement for detailed analysis of the voting results, particularly the significant "against" votes for directors Nelson Obus and Katrina Houde.
  • Confirm the appointment of BDO USA, P.C. for the upcoming fiscal year ending May 25, 2025.
  • Check subsequent filings (e.g., 10-K or 10-Q) for the financial metrics absent in this 8-K.

News